Supporting the Evidence, Investment, and Healthcare Infrastructure Needed to Advance Women's Health
Foravisét is proud to serve as the Exclusive Lead Research Partner for the 2026 U.S. Women's Health Infrastructure Report, developed in collaboration with Women's HealthX.
The report brings together perspectives from across the U.S. healthcare ecosystem—including healthcare providers, payers, pharmaceutical and life-sciences companies, and employers—to examine the structural barriers that continue to delay progress in women's health.
Beyond Innovation: The Challenge of Bringing New Therapies to Patients
Developing an innovative treatment is only part of the challenge. For new therapies to make a meaningful difference, they must also navigate a complex healthcare environment shaped by clinical evidence requirements, reimbursement policies, care delivery systems, and commercial realities.
The report examines these challenges across the women's-health landscape, exploring how gaps in research, fragmented healthcare delivery, and limitations in reimbursement and market access can prevent promising innovations from reaching the women who need them.
Why This Matters to Foravisét
At Foravisét, these questions are central to our work.
We are developing Ravisét® (FS-30), an investigational oral, non-hormonal therapy for endometriosis, a chronic condition that has long suffered from inadequate research, delayed diagnosis, and limited therapeutic innovation.
Our development strategy extends beyond establishing clinical safety and efficacy. We believe that understanding the broader impact of a treatment on women's daily lives, quality of life, healthcare utilization, and long-term outcomes is essential to demonstrating its value.
Our participation in this research initiative reflects our commitment to integrating scientific innovation, clinical evidence, and health economics into the development of new women's-health therapeutics.
Building a Stronger Foundation for Women's Health
Closing the gaps in women's healthcare requires more than scientific discoveries. It demands better evidence, a deeper understanding of disease biology, more effective healthcare systems, and investment models that recognize the full clinical and economic burden of conditions affecting women.
Through our partnership with Women's HealthX, we are pleased to contribute to a broader industry discussion about the changes needed to move women's-health innovation from promising research into accessible, effective treatment.
Read the 2026 U.S. Women's Health Infrastructure Report to explore the findings and the challenges shaping the future of women's healthcare.